113 related articles for article (PubMed ID: 31043942)
1. Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis.
Wan KM; Oehler MK
Case Rep Oncol; 2019; 12(1):59-62. PubMed ID: 31043942
[TBL] [Abstract][Full Text] [Related]
2. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H
Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
10. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ
J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
[TBL] [Abstract][Full Text] [Related]
16. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
Taheri S; Sahraian MA; Yousefi N
J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
[Next] [New Search]